References

CBTRUS statistical report: Pediatric Brain Tumor Foundation childhood and adolescent primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018

10.1093/neuonc/noac161 · 2022 · External reference

The 2021 WHO classification of Tumors of the central nervous system: a summary

10.1093/neuonc/noab106 · 2021 · External reference

The 2021 WHO classification of Tumors of the central nervous system: an update on pediatric low-grade gliomas and glioneuronal tumors

10.1111/bpa.13060 · 2022 · External reference

Integrated molecular and clinical analysis of 1,000 Pediatric low-grade gliomas

10.1016/j.ccell.2020.03.011 · 2020 · External reference

Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children’s oncology group

10.1227/neu.0b013e318214a66e · 2011 · External reference

Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German speaking Society of Pediatric Oncology and Hematology

10.1093/neuonc/nos202 · 2012 · External reference

Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy -- report from the multicenter treatment study for children and adolescents with a low grade glioma -- HIT-LGG 1996 -- of the Society of Pediatric Oncology and Hematology (GPOH)

10.1055/s-2004-832355 · 2004 · External reference

Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: a population-based study

10.1002/cncr.29907 · 2016 · External reference

Pediatric low-grade glioma: targeted therapeutics and clinical trials in the molecular era

10.1016/j.neo.2022.100857 · 2023 · External reference

Pediatric low-grade glioma: state-of-the-art and ongoing challenges

10.1093/neuonc/noad195 · 2024 · External reference

Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas

10.3171/jns.1997.86.5.0747 · 1997 · External reference

Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma

10.1200/jco.2011.34.5843 · 2012 · External reference

Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas

10.1038/ng.2611 · 2013 · External reference

Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma

10.1038/ng.2682 · 2013 · External reference

Diencephalic pediatric low-grade glioma harboring the BRAF V600E mutation presenting with various morphologies in sequential biopsy specimens

10.1007/s10014-017-0298-4 · 2017 · External reference

Pediatric low-grade glioma in the era of molecular diagnostics

10.1186/s40478-020-00902-z · 2020 · External reference

Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma

10.1038/onc.2009.73 · 2009 · External reference

Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas

10.1158/0008-5472.can-08-2097 · 2008 · External reference

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma

10.1007/s00401-011-0802-6 · 2011 · External reference

Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas

10.1158/0008-5472.can-09-1851 · 2010 · External reference

Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology

10.1007/s00401-016-1539-z · 2016 · External reference

A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas

10.1038/s41467-025-61820-z · 2025 · External reference

Association of the FGFR1 mutation with spontaneous hemorrhage in low-grade gliomas in pediatric and young adult patients

10.3171/2019.12.jns192155 · 2021 · External reference

Fibroblast growth factor receptor 1 gene mutation as a potential risk factor for spontaneous intracranial hemorrhage in pediatric low-grade glioma patients

10.1093/noajnl/vdae074 · 2024 · External reference

Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway

10.1007/s00401-016-1639-9 · 2017 · External reference

Polymorphous low-grade neuroepithelial tumor of the young: rare tumor and review of the literature

10.1177/20363613221083360 · 2022 · External reference

NF1 gene and neurofibromatosis 1

10.1093/oxfordjournals.aje.a010118 · 2000 · External reference

Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study

10.1038/bjc.2012.535 · 2013 · External reference

Cancer and central nervous system tumor surveillance in Pediatric Neurofibromatosis 1

10.1158/1078-0432.ccr-17-0589 · 2017 · External reference

Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations

10.1002/ana.21107 · 2007 · External reference

ALK in cancer: from function to therapeutic targeting

10.1038/s41568-025-00797-9 · 2025 · External reference

Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas

10.1038/s41467-019-12187-5 · 2019 · External reference

On Trk--the TrkB signal transduction pathway is an increasingly important target in cancer biology

10.1158/1078-0432.ccr-08-0651 · 2009 · External reference

Molecular and clinicopathologic features of gliomas harboring NTRK fusions

10.1186/s40478-020-00980-z · 2020 · External reference

MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism

10.1038/ng.3500 · 2016 · External reference

A single-center study of the clinicopathologic correlates of gliomas with a MYB or MYBL1 alteration

10.1007/s00401-019-02081-1 · 2019 · External reference

Dabrafenib and Trametinib in patients with Tumors with BRAF(V600E) mutations: results of the NCI-MATCH trial subprotocol H

10.1200/jco.20.00762 · 2020 · External reference

Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

10.1016/s1470-2045(21)00578-7 · 2022 · External reference

Efficacy and safety of Trametinib monotherapy or in combination with Dabrafenib in Pediatric BRAF V600-mutant low-grade glioma

10.1200/jco.22.01000 · 2023 · External reference

Dabrafenib plus Trametinib in Pediatric glioma with BRAF V600 mutations

10.1056/nejmoa2303815 · 2023 · External reference

Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas

10.1073/pnas.1219232110 · 2013 · External reference

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

10.1038/nature08833 · 2010 · External reference

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

10.1038/nature08902 · 2010 · External reference

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial

10.1016/s1470-2045(19)30277-3 · 2019 · External reference

A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric brain tumor consortium study

10.1093/neuonc/noab047 · 2021 · External reference

The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

10.1038/s41591-023-02668-y · 2024 · External reference

LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration

10.1186/s12885-024-11820-x · 2024 · External reference

Activity of Selumetinib in Neurofibromatosis type 1-related plexiform Neurofibromas

10.1056/nejmoa1605943 · 2016 · External reference

Fibroblast growth factor receptors (FGFRs): structures and small molecule inhibitors

10.3390/cells8060614 · 2019 · External reference

Debio1347, an Oral FGFR inhibitor: results from a single-Center study in Pediatric patients with recurrent or refractory FGFR-altered gliomas

10.1200/po.20.00444 · 2021 · External reference

Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial

10.1038/s41591-024-02934-7 · 2024 · External reference

Actionable tumor alterations and treatment protocol Enrollment of Pediatric and Young adult patients with refractory cancers in the National Cancer Institute-Children’s oncology group Pediatric MATCH trial

10.1200/jco.21.02838 · 2022 · External reference

FGFR alterations and potential role of FGFR inhibitors in pediatric brain tumors

10.1093/noajnl/vdaf113 · 2026 · External reference

Slipped capital femoral epiphyses: a major on-target adverse event associated with FGFR tyrosine kinase inhibitors in pediatric patients

10.1002/pbc.30410 · 2023 · External reference

Novel activating SNRNP70-ALK fusion in congenital infant-type hemispheric glioma displays clinical response to lorlatinib: a case-report

10.1038/s41698-026-01336-x · 2026 · External reference

Case report: ATIC-ALK fusion in infant-type hemispheric glioma and response to lorlatinib

10.3389/fonc.2023.1123378 · 2023 · External reference

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)

10.1093/neuonc/noac087 · 2022 · External reference

Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors

10.1093/neuonc/noab274 · 2022 · External reference

Role of surgery for optic pathway/hypothalamic astrocytomas in children

10.1215/15228517-2008-033 · 2008 · External reference

Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations

10.1093/neuonc/noz022 · 2019 · External reference

Opportunities for the treatment of NF1-associated low-grade gliomas: how to decide on the best treatment options for patients?

10.1093/neuonc/noaa201 · 2020 · External reference

Natural history of Pediatric low-grade glioma disease - first multi-state model analysis

10.7150/jca.33463 · 2019 · External reference

BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma

10.1158/1078-0432.ccr-11-0034 · 2011 · External reference

Management of pediatric low-grade glioma

10.1097/mop.0000000000000717 · 2019 · External reference

Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas

10.1158/1078-0432.ccr-11-0127 · 2011 · External reference

The senescence-associated secretory phenotype mediates oncogene-induced senescence in Pediatric Pilocytic astrocytoma

10.1158/1078-0432.ccr-18-1965 · 2019 · External reference

Canadian consensus for treatment of BRAF V600E mutated Pediatric and AYA gliomas

10.3390/curroncol31070299 · 2024 · External reference

Integrating MAPK pathway inhibition into standard-of-care therapy for pediatric low-grade glioma

10.3389/fonc.2025.1520316 · 2025 · External reference

Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma

10.1007/s11060-020-03592-8 · 2020 · External reference

Clinical experience with tovorafenib in adults with treatment-refractory high- and low-grade gliomas

10.1093/nop/npaf068 · 2025 · External reference

Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines

10.1007/s11060-024-04672-9 · 2024 · External reference

Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition

2020 · External reference

Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment

10.1093/noajnl/vdac182 · 2023 · External reference

Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: a modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma Coalition

10.1093/neuonc/noae074 · 2024 · External reference

Rebound regrowth phenomenon in patients with pediatric low-grade gliomas treated with MAPK inhibitors - a systematic review

10.3389/or.2026.1815932 · 2026 · External reference